Equities

New Nordic Healthbrands AB

NNH:STO

New Nordic Healthbrands AB

Actions
  • Price (SEK)20.00
  • Today's Change-0.20 / -0.99%
  • Shares traded4.85k
  • 1 Year change-25.93%
  • Beta0.8429
Data delayed at least 15 minutes, as of Apr 26 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

New Nordic Healthbrands AB (New Nordic) is a Sweden-based food supplement and naturopathy company. The Company develops and sells dietary supplements, herbal remedies and related personal care products. New Nordic offers products in such segments as Diet, which includes brand names Apple Cider, BioFirm and Chili Burn, among others; Vitality, which includes brands Blue Berry, Frutin, Active Liver and dida, among others, and Beauty, which includes product lines Hair Volume, Nail Strong and Skin Care, among others. New Nordic's products are available in more than 30 countries, with focus on the Nordic region and the United States.

  • Revenue in SEK (TTM)533.85m
  • Net income in SEK-6.20m
  • Incorporated2006
  • Employees73.00
  • Location
    New Nordic Healthbrands ABThe Point, Hyllie Boulevard 34MALMO 215 32SwedenSWE
  • Phone+46 446236414
  • Fax+46 40239522
  • Websitehttps://newnordic.se/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Toleranzia AB0.00-7.46m98.34m----0.6406-----0.0597-0.05970.000.7790.00-------5.21-7.45-5.43-7.78------------0.0055------11.79--63.90--
Annexin Pharmaceuticals AB (publ)0.00-46.41m100.51m4.00--15.84-----0.1887-0.18870.000.01830.00----0.00-256.08-125.42-351.79-151.33------------0.00-------8.17------
Wntresearch AB0.00-32.47m109.12m2.00--0.687-----0.1108-0.11080.000.18340.00-------134.87-100.71-166.68-123.59---------------------5.65------
Opticept Technologies AB9.15m-80.36m111.84m29.00--0.304--12.23-2.51-2.510.28448.720.0213-0.06382.37315,344.80-18.69-41.76-21.18-46.20125.8862.65-879.64-882.410.6216-14.160.0566---12.9049.1719.80--45.22--
Isofol Medical AB (publ)721.00k-37.07m115.97m3.00--0.955--160.84-0.233-0.2330.00450.75180.0041--0.0728240,333.30-21.15-66.73-26.32-88.27-4,773.37---5,141.61-1,023.62----0.00---94.37--76.80------
Bio-Works Technologies AB43.90m-56.82m116.94m38.00--2.66--2.66-1.58-1.581.221.130.5711.825.831,155,158.00-73.91-49.14-101.72-57.9061.1069.88-129.44-168.302.79--0.00--6.2346.24-26.41--1.95--
Biovica International AB5.98m-122.99m124.77m37.00--0.9911--20.87-2.42-2.420.1151.620.033-0.30538.43170,800.00-67.80-42.10-74.69-46.33110.09277.88-2,057.41-2,149.687.10--0.057--65.434.44-84.14---20.20--
New Nordic Healthbrands AB533.85m-6.20m125.14m73.00--1.18--0.2344-1.00-1.0086.1717.112.131.724.897,313,014.00-2.475.36-5.5510.5565.2367.30-1.162.380.8906-1.150.213847.969.516.28-119.41--28.36--
AlzeCure Pharma AB0.00-37.17m127.28m11.00--5.35-----0.5986-0.59860.000.38290.00----0.00-72.28-52.78-88.22-57.01------------0.00------33.91------
Bactiquant A/S19.28m-20.53m129.96m----5.76--6.74-0.6358-0.63580.59710.61330.50553.672.83---53.83-41.26-62.59-47.16-6.1412.89-106.51-71.775.43-8.540.0431---0.689--7.62------
SoftOx Solutions AS6.94m-41.82m132.39m--------19.09-1.98-1.980.3286-0.01270.081--1.60---48.81-50.83-82.20-64.58-----602.91-646.670.1745-3.45-----1.8810.0640.85--39.43--
Enorama Pharma AB1.22m-43.96m138.12m----5.80--113.40-2.16-2.160.04230.43090.03061.070.3212---110.45-64.94-277.27-94.45-267.0886.49-3,609.52-405.420.7249--0.023---37.9634.20-51.50------
ExpreS2ion Biotech Holding AB8.80m-95.99m140.85m28.00--2.31--16.01-2.12-2.120.18951.190.0832--9.91---90.72-64.80-113.72-77.46-109.74-1.94-1,090.91-532.25----0.0045--43.07-0.156119.07--19.90--
StenoCare A/S5.89m-27.53m143.74m9.00--3.51--24.41-1.29-1.290.2711.420.0967--1.25417,535.60-45.21-28.15-63.19-35.47-----467.55-371.061.30-5.540.2727---16.30---7.77------
Vo2 Cap Holding AB (publ)344.97m5.56m151.89m--27.280.6764.050.44030.10410.10416.534.200.7076--5.39--1.14-0.25641.58-0.383934.7823.361.61-0.2409--6.130.1628---26.0985.65-57.92---17.96--
SenzaGen AB49.87m-22.10m153.84m34.00--2.28--3.08-0.9136-0.91362.062.800.45943.044.031,466,765.00-20.35-25.84-27.59-29.8570.0568.62-44.31-132.291.22--0.0242--19.3990.3211.30---21.10--
Data as of Apr 26 2024. Currency figures normalised to New Nordic Healthbrands AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.05%Per cent of shares held by top holders
HolderShares% Held
Evli Fund Management Co. Ltd.as of 28 Mar 20243.00k0.05%
Data from 28 Mar 2024 - 28 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.